Effects of neurofeedback versus methylphenidate for the treatment of attention-deficit/hyperactivity disorder protocol for a systematic review and meta-analysis of head-to-head trials
Effects of neurofeedback versus methylphenidate for the treatment of attention-deficit/hyperactivity disorder protocol for a systematic review and meta-analysis of head-to-head trials
INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is developmental disorder characterized by inattention and/or hyperactivity/impulsivity. Psychostimulants, including methylphenidate (MPH), are recommended as a first-line pharmacological intervention, whereas neurofeedback (NF) has been proposed as a nonpharmacological option. The comparative effects of MPH and NF need further exploration. We will conduct a systematic review and meta-analysis of head-to-head randomized controlled trials (RCTs) comparing the efficacy and/or tolerability of MPH and NF in children/adolescents and adults with ADHD.
METHOD AND ANALYSIS: We will include published as well as unpublished data. Two investigators will independently search PubMed, OVID, ERIC, Web of Science, ClinialTrials.gov, and a set of Chinese databases, including CNKI, CQVIP, and WanFang for head-to-head RCTs comparing MPH and NF. Experts will be contacted for unpublished data. The primary outcome will be the efficacy on ADHD core symptoms, measured by the change in the severity of ADHD symptoms, from baseline to endpoint and, if available, at follow-up (at any available time point). Secondary outcomes will be: dropouts for any reasons; efficacy on neuropsychological measures (working memory, inattention, and inhibition). We will conduct subgroup analyses to assess the impact of the following variables: age; type of NF; language of publication; comorbidities. Additionally, we will carry out meta-regression analyses to investigate the effect of sponsorship, year of publication, duration of intervention, and age of participants. Sensitivity analyses will be conducted to test the robustness of the findings. Risk of bias of individual studies will be assessed using the Cochrane risk of bias tool. Analyses will be performed using Comprehensive Meta-Analysis Software.
ETHICS AND DISSEMINATION: No ethical issues are foreseen. Results from this study will be published in a peer-reviewed journal and presented at relevant national and international conferences.
TRIALS REGISTRATION NUMBER: PROSPERO CRD42018090256.
e12623
Yan, Lixia
91e87b58-89b0-4b84-a66f-2dc456d46964
Zhang, Junhua
a4628c00-1e1c-4729-8d8a-e7619a2c1edf
Yuan, Yang
1ec86511-7bf5-4ca2-a61f-9daa99b6f8a9
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
September 2018
Yan, Lixia
91e87b58-89b0-4b84-a66f-2dc456d46964
Zhang, Junhua
a4628c00-1e1c-4729-8d8a-e7619a2c1edf
Yuan, Yang
1ec86511-7bf5-4ca2-a61f-9daa99b6f8a9
Cortese, Samuele
53d4bf2c-4e0e-4c77-9385-218350560fdb
Yan, Lixia, Zhang, Junhua, Yuan, Yang and Cortese, Samuele
(2018)
Effects of neurofeedback versus methylphenidate for the treatment of attention-deficit/hyperactivity disorder protocol for a systematic review and meta-analysis of head-to-head trials.
Medicine (United States), 97 (39), .
(doi:10.1097/MD.0000000000012623).
Abstract
INTRODUCTION: Attention-deficit/hyperactivity disorder (ADHD) is developmental disorder characterized by inattention and/or hyperactivity/impulsivity. Psychostimulants, including methylphenidate (MPH), are recommended as a first-line pharmacological intervention, whereas neurofeedback (NF) has been proposed as a nonpharmacological option. The comparative effects of MPH and NF need further exploration. We will conduct a systematic review and meta-analysis of head-to-head randomized controlled trials (RCTs) comparing the efficacy and/or tolerability of MPH and NF in children/adolescents and adults with ADHD.
METHOD AND ANALYSIS: We will include published as well as unpublished data. Two investigators will independently search PubMed, OVID, ERIC, Web of Science, ClinialTrials.gov, and a set of Chinese databases, including CNKI, CQVIP, and WanFang for head-to-head RCTs comparing MPH and NF. Experts will be contacted for unpublished data. The primary outcome will be the efficacy on ADHD core symptoms, measured by the change in the severity of ADHD symptoms, from baseline to endpoint and, if available, at follow-up (at any available time point). Secondary outcomes will be: dropouts for any reasons; efficacy on neuropsychological measures (working memory, inattention, and inhibition). We will conduct subgroup analyses to assess the impact of the following variables: age; type of NF; language of publication; comorbidities. Additionally, we will carry out meta-regression analyses to investigate the effect of sponsorship, year of publication, duration of intervention, and age of participants. Sensitivity analyses will be conducted to test the robustness of the findings. Risk of bias of individual studies will be assessed using the Cochrane risk of bias tool. Analyses will be performed using Comprehensive Meta-Analysis Software.
ETHICS AND DISSEMINATION: No ethical issues are foreseen. Results from this study will be published in a peer-reviewed journal and presented at relevant national and international conferences.
TRIALS REGISTRATION NUMBER: PROSPERO CRD42018090256.
Text
Medicine MPH versus NF
- Accepted Manuscript
Text
Effects_of_neurofeedback_versus_methylphenidate.104-1
- Version of Record
More information
Accepted/In Press date: 7 September 2018
e-pub ahead of print date: 7 September 2018
Published date: September 2018
Identifiers
Local EPrints ID: 425647
URI: http://eprints.soton.ac.uk/id/eprint/425647
ISSN: 0025-7974
PURE UUID: d14404a1-5647-400b-9d10-d394f4ad154c
Catalogue record
Date deposited: 30 Oct 2018 17:30
Last modified: 06 Jun 2024 04:05
Export record
Altmetrics
Contributors
Author:
Lixia Yan
Author:
Junhua Zhang
Author:
Yang Yuan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics